Pfizer Inc
NYSE: PFE
$26.30
+$0.40 (+1.5%)
Closing Price on February 21, 2025
PFE Articles
These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices for worried investors to consider...
Published:
Last Updated:
Pfizer, in collaboration with Bain Capital, announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central...
Published:
Last Updated:
Apple shares dipped again last week, but the company managed to hold onto its rank as the top-performing Dow stock for the year to date. Shares are up nearly 30% in 2018.
Published:
Last Updated:
In 2017, 20 of the 30 stocks that comprise the Dow Jones Industrial Average posted double-digit, year-over-year share price gains. So far this year, only 9 currently show a double-digit gain.
Published:
Last Updated:
For the second consecutive trading day, all 30 Dow stocks closed lower Thursday. Exxon, Chevron, Pfizer, and McDonald's were the biggest losers.
Published:
Last Updated:
The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Pfizer shares hit multiyear highs and nearly an all-time in Monday’s session after the pharma giant announced a succession plan for its CEO.
Published:
Last Updated:
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in September.
Published:
Last Updated:
Pfizer shares slipped on Monday despite the company posting positive results from a late-stage tafamidis trial.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
Published:
Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team at Bank of America Merrill Lynch.
Published:
Last Updated:
The FDA is extending the expiration dates for certain EpiPens in light of the national shortage ahead of the back-to-school season.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.